猪口孝一
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018 Jan;109(1):182-192.
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase. Intern Med. 2018 Jan 1;57(1):17-23.
Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. Ann Hematol. 2018 Jan;97(1):51-61.
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol. 2017 Oct;96(10):1641-1652.
Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia.